|
FDA Clears Palatin Technologies' IND Filing to Commence Clinical Studies for …
PR Newswire (press release) "We are excited about the prospect of advancing PL-3994 into a Phase 2A human trial to treat asthma patients," stated Dr. Carl Spana, Palatin's Chief Executive Officer. "Existing therapies for acute exacerbations of asthma in patients unresponsive to … |
View full post on asthma – Google News